Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Jiangsu Recbio Technology Co., Ltd. Class H ( (HK:2179) ) is now available.
Jiangsu Recbio Technology Co., Ltd. announced its unaudited interim results for the first half of 2025, highlighting significant progress in its vaccine development pipeline. The company is advancing its phase III clinical trials for its HPV 9-valent vaccine and shingles vaccine, with promising safety and efficacy results. However, due to low global demand, the company has decided not to pursue further clinical development of its COVID-19 vaccine, instead focusing on future respiratory combination vaccines and monitoring mRNA vaccine technology.
The most recent analyst rating on (HK:2179) stock is a Hold with a HK$7.50 price target. To see the full list of analyst forecasts on Jiangsu Recbio Technology Co., Ltd. Class H stock, see the HK:2179 Stock Forecast page.
More about Jiangsu Recbio Technology Co., Ltd. Class H
Jiangsu Recbio Technology Co., Ltd. is a biotechnology company based in China, focusing on the development of vaccines. The company is involved in the research and development of vaccines for diseases such as HPV, shingles, respiratory syncytial virus, and COVID-19.
Average Trading Volume: 134,086
Technical Sentiment Signal: Sell
Current Market Cap: HK$3.78B
See more data about 2179 stock on TipRanks’ Stock Analysis page.